News
Spironolactone does not reduce the rate of cardiovascular death or heart failure in patients undergoing maintenance dialysis.
Dr Mariana Chavez MacGregor reports on advances from ASCO 2025, emphasizing treatment de-escalation and emerging tools like ctDNA for personalized care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback